Clinical - onset.to

October 29, 2026

Gaboxadol verändert EEG-Aktivität beim Fragilen-X-Syndrom: Pilotstudie zeigt Machbarkeit häuslicher Messungen

psychedelia-stiftung.de · Oct 29, 2026

UC San Diego study links movement-triggered chronic back pain to the brain's sense of self and explores mindfulness and psilocybin

sciencedaily.com · Oct 29, 2026 · Fadel Zeidan

Psilocybin Article Clinical Consciousness Research

October 28, 2026

LSD and psilocybin produce opposite changes in cerebral blood flow and functional connectivity, study suggests

medicalxpress.com · Oct 28, 2026 · Ingrid Fadelli

LSD Psilocybin Article Clinical +2

October 27, 2026

Weekly Psychedelic Policy Briefing: VA prepares ten treatment sites, DEA reviews five tryptamines, and cannabis hearing stays paused

psychedelicstoday.com · Oct 27, 2026 · Jack Gorsline

Psilocybin Ibogaine Article Clinical +2

BPL-003's Phase 3 dose rests on a 46-patient Phase 2b arm, while new trials test 4 mg, 8 mg and placebo

behavioralwire.com · Oct 27, 2026 · Editorial Desk

5-MeO-DMT Article Clinical Research Safety

LSD und das Sterben: Aldous Huxleys Bitte und die Erforschung psychedelischer Therapie am Lebensende

lucys-magazin.com · Oct 27, 2026

LSD Article Clinical History Therapy DE

Why pharmaceutical companies are investing billions in psychedelic drugs despite regulatory setbacks and unresolved safety questions

nature.com · Oct 27, 2026 · Lynne Peeples

Psilocybin MDMA Article Business +2

Why pharmaceutical companies continue investing billions in psychedelic drugs despite regulatory setbacks and unresolved safety questions

nature.com · Oct 27, 2026 · Lynne Peeples

Psilocybin MDMA Article Business +2

October 25, 2026

After a long, strange trip, Compass Pathways CEO Kabir Nath is close to bringing its psilocybin pill COMP360 to market

businessinsider.com · Oct 25, 2026

Psilocybin Article Business Clinical Industry

Psilocybin's controlled evidence for alcohol use disorder ends at week 36, while an uncontrolled repeat-dose follow-up found only brief reductions

behavioralwire.com · Oct 25, 2026 · Editorial Desk

Psilocybin Article Clinical Research Safety

October 23, 2026

MDMA-assisted therapy for PTSD may gain FDA approval by early 2027, but a severe shortage of qualified therapists could limit access

nypost.com · Oct 23, 2026 · McKenzie Beard

MDMA Article Clinical Policy Therapy

Before European Approvals: Norway, Germany, Switzerland, the UK and Estonia Build Psychedelic Access Pathways at TAIP 2026

psychedelicalpha.com · Oct 23, 2026 · Ryan Khan

Psilocybin Ketamine Article Clinical +2

Sechsstündige intravenöse DMT-Infusion bei 29 gesunden Erwachsenen in einer kontrollierten Studie untersucht

psychedelia-stiftung.de · Oct 23, 2026

DMT Article Clinical Research Safety DE

October 22, 2026

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Federal Officials Weigh In on Psychedelic Access

psychedelicalpha.com · Oct 22, 2026

Ibogaine Article Clinical Policy Safety

MDA verursacht länger anhaltende Wirkungen und mehr Nebenwirkungen als MDMA in einer randomisierten Cross-over-Studie

psychedelia-stiftung.de · Oct 22, 2026

MDMA Article Clinical Research Safety DE

October 21, 2026

New human data suggests psilocybin may reduce inflammation and mitochondrial stress in Parkinson's disease

npr.org · Oct 21, 2026 · Will Stone

Psilocybin Article Clinical Research Safety

ICER to assess synthetic psilocybin therapy COMP360 for treatment-resistant depression, with public comments open through November 10, 2026

icer.org · Oct 21, 2026

Psilocybin Article Clinical Policy Research

ICER assessment of treatment-resistant depression and synthetic psilocybin from COMPASS Pathways

icer.org · Oct 21, 2026

Psilocybin Article Clinical Research

October 20, 2026

Psilocybin PTSD evidence appeared first in an SEC filing, exposing how media, journals and registries show different levels of trial maturity

behavioralwire.com · Oct 20, 2026 · Editorial Desk

Psilocybin Article Clinical Mainstream Research

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

psychedelicalpha.com · Oct 20, 2026 · Josh Hardman

Psilocybin Ibogaine Podcast Clinical +2

CBD-dominante Cannabisprodukte stehen mit geringeren kurzfristigen Einbußen bei bestimmten kognitiven Leistungen in Verbindung

lucys-magazin.com · Oct 20, 2026

Cannabis Article Clinical Research Safety DE

Psychedelische Ikonen: Humphry Osmond und seine Forschung zu LSD, Schizophrenie und halluzinogenen Wirkungen

lucys-magazin.com · Oct 20, 2026

LSD Article Clinical History Research DE

October 18, 2026

Eine einzelne Psilocybin-Dosis linderte Depressionen innerhalb weniger Tage, doch der Vorteil gegenüber Placebo verschwand binnen eines Jahres

psypost.org · Oct 18, 2026 · Vladimir Hedrih

Psilocybin Article Clinical Research Therapy DE

October 17, 2026

What if post-psychedelic difficulties are sometimes forms of health anxiety? When fear of harm might sustain the harm

ecstaticintegration.org · Oct 17, 2026 · Jules Evans

Article Clinical Integration Safety

October 16, 2026

A small Oregon feasibility study finds group psilocybin therapy feasible for low-income adults with depression, but efficacy remains uncertain

psypost.org · Oct 16, 2026 · Eric W. Dolan

Psilocybin Article Clinical HarmReduction Research